U.S. FDA· FDA·· 3 hours agoPickScore93
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
In brief
On October 19, 2026, the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with previously untreated, MSI-H or dMMR Stage II/III locally advanced rectal cancer, based on single-arm trial data.
Why it matters
The article gives specific cCR12 and ORR values with confidence intervals, letting readers compare neoadjuvant immunotherapy regimens for dMMR rectal cancer.
Source: U.S. FDA